enGene (NASDAQ:ENGN) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPS

enGene (NASDAQ:ENGN) issued its quarterly earnings results on Monday. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.11), Zacks reports.

enGene Stock Performance

Shares of ENGN traded down $0.01 during trading hours on Monday, reaching $5.24. 27,537 shares of the company traded hands, compared to its average volume of 131,819. enGene has a 1-year low of $4.42 and a 1-year high of $18.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 16.87 and a current ratio of 16.87. The stock has a market cap of $267.12 million, a P/E ratio of -9.03 and a beta of -0.61. The stock’s fifty day moving average is $6.68 and its 200 day moving average is $7.16.

Analyst Upgrades and Downgrades

Several brokerages have commented on ENGN. Piper Sandler started coverage on shares of enGene in a research report on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 price target on the stock. HC Wainwright began coverage on enGene in a research note on Monday, December 23rd. They issued a “buy” rating and a $25.00 price target on the stock. UBS Group lowered enGene from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th. Raymond James began coverage on shares of enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, Citizens Jmp upgraded enGene to a “strong-buy” rating in a report on Monday, November 18th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, enGene presently has an average rating of “Buy” and a consensus target price of $25.89.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.